{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:01:21Z","timestamp":1793908881183,"version":"4.8.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Detecting malignant peripheral nerve sheath tumors (MPNSTs) remains difficult. <jats:sup>18<\/jats:sup>F-FDG PET-CT has been shown helpful, but ideal threshold values of semi-quantitative markers remain unclear, partially because of variation among scanners. Using EU-certified scanners diagnostic accuracy of ideal and commonly used <jats:sup>18<\/jats:sup>F-FDG PET-CT thresholds were investigated and differences between adult and pediatric lesions were evaluated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A retrospective cohort study was performed including patients from two hospitals with a clinical or radiological suspicion of MPNST between 2013 and 2019. Several markers were studied for ideal threshold values and differences among adults and children. A diagnostic algorithm was subsequently developed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Sixty patients were included (10 MPNSTs). Ideal threshold values were 5.8 for SUVmax (sensitivity 0.70, specificity 0.92), 5.0 for SUVpeak (sensitivity 0.70, specificity 0.97), 1.7 for TLmax (sensitivity 0.90, specificity 0.86), and 2.3 for TLmean (sensitivity 0.90, specificity 0.79). The standard TLmean threshold value of 2.0 yielded a sensitivity of 0.90 and specificity of 0.74, while the standard SUVmax threshold value of 3.5 yielded a sensitivity of 0.80 and specificity of 0.63. SUVmax and adjusted SUV for lean body mass (SUL) were lower in children, but tumor-to-liver ratios were similar in adult and pediatric lesions. Using TLmean\u2009&gt;\u20092.0 or TLmean\u2009&lt;\u20092.0 and SUVmax\u2009&gt;\u20093.5, a sensitivity and specificity of 1.00 and 0.63 can be achieved.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p><jats:sup>18<\/jats:sup>F-FDG PET-CT offers adequate accuracy to detect MPNSTs. SUV values in pediatric MPNSTs may be lower, but tumor-to-liver ratios are not. By combining TLmean and SUVmax values, a 100% sensitivity can be achieved with acceptable specificity.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11060-021-03936-y","type":"journal-article","created":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T13:02:48Z","timestamp":1642078968000},"page":"559-567","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Diagnostic value of 18F-FDG PET-CT in detecting malignant peripheral nerve sheath tumors among adult and pediatric neurofibromatosis type 1 patients"],"prefix":"10.1007","volume":"156","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4707-0319","authenticated-orcid":false,"given":"Ritch T. J.","family":"Geitenbeek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura H.","family":"Graven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn P. G.","family":"Broen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique H. M. E.","family":"Anten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochem A. J.","family":"van der Pol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis","family":"Verhoef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Taal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,13]]},"reference":[{"issue":"2","key":"3936_CR1","doi-asserted-by":"publisher","first-page":"246","DOI":"10.3171\/jns.2005.102.2.0246","volume":"102","author":"DH Kim","year":"2005","unstructured":"Kim DH, Murovic JA, Tiel RL, Moes G, Kline DG (2005) A series of 397 peripheral neural sheath tumors: 30-year experience at Louisiana State University Health Sciences Center. J Neurosurg 102(2):246\u2013255. https:\/\/doi.org\/10.3171\/jns.2005.102.2.0246","journal-title":"J Neurosurg"},{"issue":"2","key":"3936_CR2","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3171\/2015.6.JNS15596","volume":"125","author":"N Montano","year":"2016","unstructured":"Montano N, D\u2019Alessandris QG, D\u2019Ercole M et al (2016) Tumors of the peripheral nervous system: analysis of prognostic factors in a series with long-term follow-up and review of the literature. J Neurosurg 125(2):363\u2013371. https:\/\/doi.org\/10.3171\/2015.6.JNS15596","journal-title":"J Neurosurg"},{"issue":"1","key":"3936_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/(SICI)1096-8628(19990326)89:1<1::AID-AJMG3>3.0.CO;2-8","volume":"89","author":"JM Friedman","year":"1999","unstructured":"Friedman JM (1999) Epidemiology of neurofibromatosis type 1. Am J Med Genet 89(1):1\u20136","journal-title":"Am J Med Genet"},{"issue":"6","key":"3936_CR4","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S0022-3476(05)80639-0","volume":"116","author":"R Listernick","year":"1990","unstructured":"Listernick R, Charrow J (1990) Neurofibromatosis type 1 in childhood. J Pediatr 116(6):845\u2013853. https:\/\/doi.org\/10.1016\/S0022-3476(05)80639-0","journal-title":"J Pediatr"},{"issue":"2","key":"3936_CR5","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s13311-017-0518-y","volume":"14","author":"V Staedtke","year":"2017","unstructured":"Staedtke V, Bai R-Y, Blakeley JO (2017) Cancer of the peripheral nerve in neurofibromatosis type 1. Neurotherapeutics 14(2):298\u2013306. https:\/\/doi.org\/10.1007\/s13311-017-0518-y","journal-title":"Neurotherapeutics"},{"issue":"7","key":"3936_CR6","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1097\/PAS.0000000000000655","volume":"40","author":"S Le Guellec","year":"2016","unstructured":"Le Guellec S, Decouvelaere A-V, Filleron T et al (2016) Malignant peripheral nerve sheath tumor is a challenging diagnosis: a systematic pathology review, immunohistochemistry, and molecular analysis in 160 patients from the french sarcoma group database. Am J Surg Pathol 40(7):896\u2013908. https:\/\/doi.org\/10.1097\/PAS.0000000000000655","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"3936_CR7","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1097\/SLA.0000000000000869","volume":"260","author":"MF Brennan","year":"2014","unstructured":"Brennan MF, Antonescu CR, Moraco N, Singer S (2014) Lessons learned from the study of 10,000 patients with soft tissue sarcoma. Ann Surg 260(3):416\u2013422. https:\/\/doi.org\/10.1097\/SLA.0000000000000869","journal-title":"Ann Surg"},{"issue":"5","key":"3936_CR8","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1136\/jmg.39.5.311","volume":"39","author":"DGR Evans","year":"2002","unstructured":"Evans DGR, Baser ME, McGaughran J, Sharif S, Howard E, Moran A (2002) Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 39(5):311\u2013314. https:\/\/doi.org\/10.1136\/jmg.39.5.311","journal-title":"J Med Genet"},{"issue":"2","key":"3936_CR9","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1136\/jmg.2006.045906","volume":"44","author":"RE Ferner","year":"2007","unstructured":"Ferner RE, Huson SM, Thomas N et al (2007) Guidelines for the diagnosis and management of individuals with neurofibromatosis. J Med Genet 44(2):81\u201388. https:\/\/doi.org\/10.1136\/jmg.2006.045906","journal-title":"J Med Genet"},{"key":"3936_CR10","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ejca.2015.12.015","volume":"56","author":"T Valentin","year":"2016","unstructured":"Valentin T, Le Cesne A, Ray-Coquard I et al (2016) Management and prognosis of malignant peripheral nerve sheath tumors: the experience of the French Sarcoma Group (GSF-GETO). Eur J Cancer 56:77\u201384. https:\/\/doi.org\/10.1016\/j.ejca.2015.12.015","journal-title":"Eur J Cancer"},{"key":"3936_CR11","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ejca.2019.10.014","volume":"124","author":"E Martin","year":"2019","unstructured":"Martin E, Coert JH, Flucke UE et al (2019) A nationwide cohort study on treatment and survival in patients with malignant peripheral nerve sheath tumours. Eur J Cancer 124:77\u201387. https:\/\/doi.org\/10.1016\/j.ejca.2019.10.014","journal-title":"Eur J Cancer"},{"issue":"3","key":"3936_CR12","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1245\/s10434-011-1978-7","volume":"19","author":"C-CH Stucky","year":"2012","unstructured":"Stucky C-CH, Johnson KN, Gray RJ et al (2012) Malignant peripheral nerve sheath tumors (MPNST): the mayo clinic experience. Ann Surg Oncol 19(3):878\u2013885. https:\/\/doi.org\/10.1245\/s10434-011-1978-7","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"3936_CR13","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.3171\/2019.7.JNS191353","volume":"133","author":"CN Nelson","year":"2020","unstructured":"Nelson CN, Dombi E, Rosenblum JS et al (2020) Safe marginal resection of atypical neurofibromas in neurofibromatosis type 1. J Neurosurg 133(5):1516\u20131526. https:\/\/doi.org\/10.3171\/2019.7.JNS191353","journal-title":"J Neurosurg"},{"issue":"2","key":"3936_CR14","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s00423-019-01851-5","volume":"405","author":"MM Hajiabadi","year":"2020","unstructured":"Hajiabadi MM, Campos B, Sedlaczek O et al (2020) Interdisciplinary approach allows minimally invasive, nerve-sparing removal of retroperitoneal peripheral nerve sheath tumors. Langenbeck\u2019s Arch Surg 405(2):199\u2013205. https:\/\/doi.org\/10.1007\/s00423-019-01851-5","journal-title":"Langenbeck\u2019s Arch Surg"},{"issue":"1","key":"3936_CR15","doi-asserted-by":"publisher","first-page":"142","DOI":"10.3171\/2012.9.JNS101610","volume":"118","author":"GP Dunn","year":"2013","unstructured":"Dunn GP, Spiliopoulos K, Plotkin SR et al (2013) Role of resection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis type 1: clinical article. J Neurosurg 118(1):142\u2013148. https:\/\/doi.org\/10.3171\/2012.9.JNS101610","journal-title":"J Neurosurg"},{"key":"3936_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/6162182","volume":"2016","author":"D Tovmassian","year":"2016","unstructured":"Tovmassian D, Abdul Razak M, London K (2016) The role of [18F]FDG-PET\/CT in predicting malignant transformation of plexiform neurofibromas in neurofibromatosis-1. Int J Surg Oncol 2016:1\u20137. https:\/\/doi.org\/10.1155\/2016\/6162182","journal-title":"Int J Surg Oncol"},{"issue":"2","key":"3936_CR17","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00330-013-3020-x","volume":"24","author":"J Salamon","year":"2014","unstructured":"Salamon J, Veldhoen S, Apostolova I et al (2014) F-18-FDG PET\/CT for detection of malignant peripheral nerve sheath tumours in neurofibromatosis type 1: tumour-to-liver ratio is superior to an SUVmax cut-off. Eur Radiol 24(2):405\u2013412. https:\/\/doi.org\/10.1007\/s00330-013-3020-x","journal-title":"Eur Radiol"},{"issue":"5","key":"3936_CR18","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s00259-012-2314-6","volume":"40","author":"J Salamon","year":"2013","unstructured":"Salamon J, Derlin T, Bannas P et al (2013) Evaluation of intratumoural heterogeneity on 18F-FDG PET\/CT for characterization of peripheral nerve sheath tumours in neurofibromatosis type 1. Eur J Nucl Med Mol Imaging 40(5):685\u2013692. https:\/\/doi.org\/10.1007\/s00259-012-2314-6","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"3936_CR19","doi-asserted-by":"publisher","first-page":"e0143305","DOI":"10.1371\/journal.pone.0143305","volume":"10","author":"J Salamon","year":"2015","unstructured":"Salamon J, Papp L, T\u00f3th Z et al (2015) Nerve sheath tumors in neurofibromatosis type 1: assessment of whole-body metabolic tumor burden using F-18-FDG PET\/CT. PLoS ONE 10(12):e0143305. https:\/\/doi.org\/10.1371\/journal.pone.0143305","journal-title":"PLoS ONE"},{"issue":"11","key":"3936_CR20","doi-asserted-by":"publisher","first-page":"e1076","DOI":"10.1212\/WNL.0000000000008092","volume":"93","author":"S Ahlawat","year":"2019","unstructured":"Ahlawat S, Blakeley JO, Rodriguez FJ, Fayad LM (2019) Imaging biomarkers for malignant peripheral nerve sheath tumors in neurofibromatosis type 1. Neurology 93(11):e1076\u2013e1084. https:\/\/doi.org\/10.1212\/WNL.0000000000008092","journal-title":"Neurology"},{"issue":"1","key":"3936_CR21","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1097\/RLU.0b013e318266ce84","volume":"38","author":"T Derlin","year":"2013","unstructured":"Derlin T, Tornquist K, M\u00fcnster S et al (2013) Comparative effectiveness of 18F-FDG PET\/CT versus whole-body MRI for detection of malignant peripheral nerve sheath tumors in neurofibromatosis type 1. Clin Nucl Med 38(1):e19\u2013e25. https:\/\/doi.org\/10.1097\/RLU.0b013e318266ce84","journal-title":"Clin Nucl Med"},{"issue":"5","key":"3936_CR22","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1007\/s00259-008-1038-0","volume":"36","author":"VS Warbey","year":"2009","unstructured":"Warbey VS, Ferner RE, Dunn JT, Calonje E, O\u2019Doherty MJ (2009) FDG PET\/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1. Eur J Nucl Med Mol Imaging 36(5):754\u2013757. https:\/\/doi.org\/10.1007\/s00259-008-1038-0","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"3936_CR23","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1093\/annonc\/mdm450","volume":"19","author":"RE Ferner","year":"2008","unstructured":"Ferner RE, Golding JF, Smith M et al (2008) [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study. Ann Oncol 19(2):390\u2013394. https:\/\/doi.org\/10.1093\/annonc\/mdm450","journal-title":"Ann Oncol"},{"key":"3936_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaa280","author":"E Martin","year":"2020","unstructured":"Martin E, Geitenbeek RTJ, Coert JH et al (2020) A Bayesian approach for diagnostic accuracy of malignant peripheral nerve sheath tumors: a systematic review and meta-analysis. Neuro Oncol. https:\/\/doi.org\/10.1093\/neuonc\/noaa280","journal-title":"Neuro Oncol"},{"issue":"1","key":"3936_CR25","doi-asserted-by":"publisher","first-page":"e26733","DOI":"10.1002\/pbc.26733","volume":"65","author":"AA Azizi","year":"2018","unstructured":"Azizi AA, Slavc I, Theisen BE et al (2018) Monitoring of plexiform neurofibroma in children and adolescents with neurofibromatosis type 1 by [(18) F]FDG-PET imaging. Is it of value in asymptomatic patients. Pediatr Blood Cancer 65(1):e26733. https:\/\/doi.org\/10.1002\/pbc.26733","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"3936_CR26","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1007\/s00259-010-1386-4","volume":"37","author":"M Moharir","year":"2010","unstructured":"Moharir M, London K, Howman-Giles R et al (2010) Utility of positron emission tomography for tumour surveillance in children with neurofibromatosis type 1. Eur J Nucl Med Mol Imaging 37(7):1309\u20131317. https:\/\/doi.org\/10.1007\/s00259-010-1386-4","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"3936_CR27","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s11060-012-0840-5","volume":"108","author":"LL Tsai","year":"2012","unstructured":"Tsai LL, Drubach L, Fahey F, Irons M, Voss S, Ullrich NJ (2012) [18F]-Fluorodeoxyglucose positron emission tomography in children with neurofibromatosis type 1 and plexiform neurofibromas: correlation with malignant transformation. J Neurooncol 108(3):469\u2013475. https:\/\/doi.org\/10.1007\/s11060-012-0840-5","journal-title":"J Neurooncol"},{"issue":"4A","key":"3936_CR28","first-page":"1957","volume":"27","author":"RE Friedrich","year":"2007","unstructured":"Friedrich RE, Hartmann M, Mautner VF (2007) Malignant peripheral nerve Sheath tumors (MPNST) in NF1-affected children. Anticancer Res 27(4A):1957\u20131960","journal-title":"Anticancer Res"},{"issue":"9","key":"3936_CR29","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.2967\/jnumed.113.136986","volume":"55","author":"AK Tahari","year":"2014","unstructured":"Tahari AK, Chien D, Azadi JR, Wahl RL (2014) Optimum lean body formulation for correction of standardized uptake value in PET imaging. J Nucl Med 55(9):1481\u20131484. https:\/\/doi.org\/10.2967\/jnumed.113.136986","journal-title":"J Nucl Med"},{"issue":"6","key":"3936_CR30","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1053\/j.sult.2010.10.001","volume":"31","author":"PE Kinahan","year":"2010","unstructured":"Kinahan PE, Fletcher JW (2010) Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy. Semin Ultrasound, CT MRI 31(6):496\u2013505. https:\/\/doi.org\/10.1053\/j.sult.2010.10.001","journal-title":"Semin Ultrasound, CT MRI"},{"issue":"8","key":"3936_CR31","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1007\/s00256-016-2394-7","volume":"45","author":"SM Broski","year":"2016","unstructured":"Broski SM, Johnson GB, Howe BM et al (2016) Evaluation of 18F-FDG PET and MRI in differentiating benign and malignant peripheral nerve sheath tumors. Skeletal Radiol 45(8):1097\u20131105. https:\/\/doi.org\/10.1007\/s00256-016-2394-7","journal-title":"Skeletal Radiol"},{"issue":"10","key":"3936_CR32","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0151-9638(07)92528-4","volume":"134","author":"B Bensaid","year":"2007","unstructured":"Bensaid B, Giammarile F, Mognetti T et al (2007) Int\u00e9r\u00eat de la tomographie par \u00e9mission de positons au fluorod\u00e9oxyglucose 18 dans la d\u00e9tection des neurofibrosarcomes au cours de la neurofibromatose de type 1. Ann Dermatol Venereol 134(10):735\u2013741. https:\/\/doi.org\/10.1016\/S0151-9638(07)92528-4","journal-title":"Ann Dermatol Venereol"},{"issue":"2","key":"3936_CR33","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1002\/cncr.24755","volume":"116","author":"MR Benz","year":"2010","unstructured":"Benz MR, Czernin J, Dry SM et al (2010) Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign. Cancer 116(2):451\u2013458. https:\/\/doi.org\/10.1002\/cncr.24755","journal-title":"Cancer"},{"issue":"11","key":"3936_CR34","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1007\/s00259-017-3733-1","volume":"44","author":"GJR Cook","year":"2017","unstructured":"Cook GJR, Lovat E, Siddique M, Goh V, Ferner R, Warbey VS (2017) Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of (18)F-FDG PET. Eur J Nucl Med Mol Imaging 44(11):1845\u20131852. https:\/\/doi.org\/10.1007\/s00259-017-3733-1","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5\u20136","key":"3936_CR35","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.mednuc.2019.05.001LK-","volume":"43","author":"L Lerman","year":"2019","unstructured":"Lerman L, Zehou O, Ortonne N et al (2019) Interest of 18F-FDG PET\/CT in neurofibromatosis type 1, 10-year experience from the national reference centre Henri-Mondor. Med Nucl 43(5\u20136):370\u2013380. https:\/\/doi.org\/10.1016\/j.mednuc.2019.05.001LK-","journal-title":"Med Nucl"},{"issue":"3\u20134","key":"3936_CR36","doi-asserted-by":"publisher","first-page":"184","DOI":"10.2152\/jmi.60.184","volume":"60","author":"H Nose","year":"2013","unstructured":"Nose H, Otsuka H, Otomi Y et al (2013) Correlations between F-18 FDG PET\/CT and pathological findings in soft tissue lesions. J Med Invest 60(3\u20134):184\u2013190","journal-title":"J Med Invest"},{"issue":"3","key":"3936_CR37","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1007\/s00259-018-4227-5","volume":"46","author":"CP Reinert","year":"2019","unstructured":"Reinert CP, Schuhmann MU, Bender B et al (2019) Comprehensive anatomical and functional imaging in patients with type I neurofibromatosis using simultaneous FDG-PET\/MRI. Eur J Nucl Med Mol Imaging 46(3):776\u2013787. https:\/\/doi.org\/10.1007\/s00259-018-4227-5","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"3936_CR38","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s00259-012-2314-6","volume":"40","author":"J Salamon","year":"2013","unstructured":"Salamon J, Derlin T, Bannas P et al (2013) Evaluation of intratumoural heterogeneity on (1)(8)F-FDG PET\/CT for characterization of peripheral nerve sheath tumours in neurofibromatosis type 1. Eur J Nucl Med Mol Imaging 40(5):685\u2013692. https:\/\/doi.org\/10.1007\/s00259-012-2314-6","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3936_CR39","doi-asserted-by":"publisher","first-page":"4627521","DOI":"10.1155\/2019\/4627521","volume":"2019","author":"M Schwabe","year":"2019","unstructured":"Schwabe M, Spiridonov S, Yanik EL et al (2019) How effective are noninvasive tests for diagnosing malignant peripheral nerve sheath tumors in patients with neurofibromatosis type 1? Diagnosing MPNST in NF1 patients. Sarcoma 2019:4627521. https:\/\/doi.org\/10.1155\/2019\/4627521","journal-title":"Sarcoma"},{"issue":"5","key":"3936_CR40","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s00259-008-1038-0","volume":"36","author":"VS Warbey","year":"2009","unstructured":"Warbey VS, Ferner RE, Dunn JT, Calonje E, O\u2019Doherty MJ (2009) [18F]FDG PET\/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1. Eur J Nucl Med Mol Imaging 36(5):751\u2013757. https:\/\/doi.org\/10.1007\/s00259-008-1038-0","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"3936_CR41","doi-asserted-by":"publisher","first-page":"e85954","DOI":"10.1371\/journal.pone.0085954","volume":"9","author":"P Combemale","year":"2014","unstructured":"Combemale P, Valeyrie-Allanore L, Giammarile F et al (2014) Utility of 18F-FDG PET with a semi-quantitative index in the detection of sarcomatous transformation in patients with neurofibromatosis type 1. PLoS ONE 9(2):e85954. https:\/\/doi.org\/10.1371\/journal.pone.0085954","journal-title":"PLoS ONE"},{"issue":"3","key":"3936_CR42","doi-asserted-by":"publisher","first-page":"328","DOI":"10.4103\/0019-509X.84945","volume":"48","author":"A Chhabra","year":"2011","unstructured":"Chhabra A, Soldatos T, Durand DJ, Carrino JA, McCarthy EF, Belzberg AJ (2011) The role of magnetic resonance imaging in the diagnostic evaluation of malignant peripheral nerve sheath tumors. Indian J Cancer 48(3):328\u2013334. https:\/\/doi.org\/10.4103\/0019-509X.84945","journal-title":"Indian J Cancer"},{"issue":"4 Suppl","key":"3936_CR43","doi-asserted-by":"publisher","first-page":"A160","DOI":"10.1227\/01.NEU.0000337597.18599.D3","volume":"65","author":"K Karabatsou","year":"2009","unstructured":"Karabatsou K, Kiehl T-R, Wilson DM, Hendler A, Guha A (2009) Potential role of 18fluorodeoxyglucose-positron emission tomography\/computed tomography in differentiating benign neurofibroma from malignant peripheral nerve sheath tumor associated with neurofibromatosis 1. Neurosurgery 65(4 Suppl):A160\u2013A170","journal-title":"Neurosurgery"},{"issue":"3","key":"3936_CR44","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1136\/jnnp.68.3.353","volume":"68","author":"RE Ferner","year":"2000","unstructured":"Ferner RE, Lucas JD, O\u2019Doherty MJ et al (2000) Evaluation of 18fluorodeoxyglucose positron emission tomography (18FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1. J Neurol Neurosurg Psychiatr 68(3):353\u2013357. https:\/\/doi.org\/10.1136\/jnnp.68.3.353","journal-title":"J Neurol Neurosurg Psychiatr"},{"issue":"3","key":"3936_CR45","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2967\/jnumed.114.142372","volume":"56","author":"A Chirindel","year":"2015","unstructured":"Chirindel A, Chaudhry M, Blakeley JO, Wahl R (2015) 18F-FDG PET\/CT qualitative and quantitative evaluation in neurofibromatosis type 1 patients for detection of malignant transformation: comparison of early to delayed imaging with and without liver activity normalization. J Nucl Med 56(3):379\u2013385. https:\/\/doi.org\/10.2967\/jnumed.114.142372","journal-title":"J Nucl Med"},{"issue":"4","key":"3936_CR46","doi-asserted-by":"publisher","first-page":"928","DOI":"10.2214\/AJR.07.2060","volume":"189","author":"MA Bredella","year":"2007","unstructured":"Bredella MA, Torriani M, Hornicek F et al (2007) Value of PET in the assessment of patients with neurofibromatosis type 1. AJR 189(4):928\u2013935. https:\/\/doi.org\/10.2214\/AJR.07.2060","journal-title":"AJR"},{"key":"3936_CR47","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1002\/1097-0142(19860515)57:10<2006::AID-CNCR2820571022>3.0.CO;2-6","volume":"57","author":"BS Ducatman","year":"1986","unstructured":"Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM, Ilstrup DM (1986) Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer J 57:2006\u20132021","journal-title":"Cancer J"},{"key":"3936_CR48","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0360-3016(98)00223-5","volume":"42","author":"WW Wong","year":"1998","unstructured":"Wong WW, Hirose T, Scheithauer BW, Schild SE, Gunderson LL (1998) Malignant peripheral nerve sheath tumor: analysis of treatment outcome. Int J Radiat Oncol Biol Phys 42:351\u2013360","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-021-03936-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-021-03936-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-021-03936-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T14:29:16Z","timestamp":1645453756000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-021-03936-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,13]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["3936"],"URL":"https:\/\/doi.org\/10.1007\/s11060-021-03936-y","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,13]]},"assertion":[{"value":"20 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No author has any form of disclosure.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethics Committee of participating centers with waiver of individual patient consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}